Author

V. Krystof

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

E. Reznickova· 3 shared R. Jorda· 3 shared M. Perina· 2 shared A. Dolnikova· 1 shared H. Dostalova· 1 shared J. Skerlova· 1 shared K. Kozlanska· 1 shared L. Havlicek· 1 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

E. Reznickova

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Characterization of new highly selective pyrazolopyrimidine inhibitor of CDK7

M. Kovalova, L. Havlicek, S. Djukic, J. Skerlova, M. Perina, T. Pospisil, E. Reznickova, P. Rezacova, R. Jorda, V. Krystof

This paper characterizes a new CDK7 inhibitor, LGR6768, showing nanomolar potency and selectivity, with structural and cellular evidence supporting its mechanism and therapeutic potential.

bioRxiv · Feb 24, 2023Cancer Biology

Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines

H. Dostalova, R. Jorda, E. Reznickova, V. Krystof

This study investigates the anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines and finds it inhibits HER2 signaling and downstream kinases.

bioRxiv · Feb 23, 2023Cancer Biology

Synthesis and structural optimization of 2,7,9-trisubstituted purin-8-ones as FLT3-ITD inhibitors

M. Tomanova, K. Kozlanska, R. Jorda, L. Jedinak, T. Havlikova, E. Reznickova, M. Perina, P. Klener, A. Dolnikova, P. Cankar, V. Krystof

The paper designs and evaluates 2,7,9-trisubstituted purin-8-ones as FLT3-ITD inhibitors, identifying compound 15a with improved selectivity and activity in vitro and in vivo.

bioRxiv · Dec 10, 2022Pharmacology & Toxicology